Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bowman Birk Inhibitor Concentrate in Oral Leukoplakia
NCT00330382Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 1999
- Primary completion
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bowman-birk inhibitor in oral leukoplakia, sponsored by National Cancer Institute. Started Jan 1999; status: completed.
02
Drugs
bowman-birk inhibitor
03
Conditions
oral leukoplakia
Beyond the preview
Go deeper on NCT00330382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330382.